Identifying Cardiac Amyloid in Aortic Stenosis: ECV Quantification by CT in TAVR Patients
Paul R Scully, Kush P Patel, Bunny Saberwal, Ernst Klotz, João B Augusto, George D Thornton, Rebecca K Hughes, Charlotte Manisty, Guy Lloyd, James D Newton, Nikant Sabharwal, Andrew Kelion, Simon Kennon, Muhiddin Ozkor, Michael Mullen, Neil Hartman, João L Cavalcante, Leon J Menezes, Philip N Hawkins, Thomas A Treibel, James C Moon, Francesca Pugliese, Paul R Scully, Kush P Patel, Bunny Saberwal, Ernst Klotz, João B Augusto, George D Thornton, Rebecca K Hughes, Charlotte Manisty, Guy Lloyd, James D Newton, Nikant Sabharwal, Andrew Kelion, Simon Kennon, Muhiddin Ozkor, Michael Mullen, Neil Hartman, João L Cavalcante, Leon J Menezes, Philip N Hawkins, Thomas A Treibel, James C Moon, Francesca Pugliese
Abstract
Objectives: The purpose of this study was to validate computed tomography measured ECV (ECVCT) as part of routine evaluation for the detection of cardiac amyloid in patients with aortic stenosis (AS)-amyloid.
Background: AS-amyloid affects 1 in 7 elderly patients referred for transcatheter aortic valve replacement (TAVR). Bone scintigraphy with exclusion of a plasma cell dyscrasia can diagnose transthyretin-related cardiac amyloid noninvasively, for which novel treatments are emerging. Amyloid interstitial expansion increases the myocardial extracellular volume (ECV).
Methods: Patients with severe AS underwent bone scintigraphy (Perugini grade 0, negative; Perugini grades 1 to 3, increasingly positive) and routine TAVR evaluation CT imaging with ECVCT using 3- and 5-min post-contrast acquisitions. Twenty non-AS control patients also had ECVCT performed using the 5-min post-contrast acquisition.
Results: A total of 109 patients (43% male; mean age 86 ± 5 years) with severe AS and 20 control subjects were recruited. Sixteen (15%) had AS-amyloid on bone scintigraphy (grade 1, n = 5; grade 2, n = 11). ECVCT was 32 ± 3%, 34 ± 4%, and 43 ± 6% in Perugini grades 0, 1, and 2, respectively (p < 0.001 for trend) with control subjects lower than lone AS (28 ± 2%; p < 0.001). ECVCT accuracy for AS-amyloid detection versus lone AS was 0.87 (0.95 for 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid Perugini grade 2 only), outperforming conventional electrocardiogram and echocardiography parameters. One composite parameter, the voltage/mass ratio, had utility (similar AUC of 0.87 for any cardiac amyloid detection), although in one-third of patients, this could not be calculated due to bundle branch block or ventricular paced rhythm.
Conclusions: ECVCT during routine CT TAVR evaluation can reliably detect AS-amyloid, and the measured ECVCT tracks the degree of infiltration. Another measure of interstitial expansion, the voltage/mass ratio, also performed well.
Keywords: aortic stenosis; cardiac amyloidosis; computed tomography; extracellular volume.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Figures
References
- Lung B. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24:1231–1243.
- Thaden J.J., Nkomo V.T., Enriquez-Sarano M. The global burden of aortic stenosis. Prog Cardiovasc Dis. 2014;56:565–571.
- Lindroos M., Kupari M., Heikkilä J., Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993;21:1220–1225.
- Turina J., Hess O., Sepulcri F., Krayenbuehl H.P. Spontaneous course of aortic valve disease. Eur Heart J. 1987;8:471–483.
- Leon M.B., Smith C.R., Mack M.J. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–1620.
- Mack M.J., Leon M.B., Thourani V.H., Makkar R., Kodali S.K., Russo M. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695–1705.
- Tanskanen M., Peuralinna T., Polvikoski T. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau : a population-based autopsy study. Ann Med. 2008;40:232–239.
- Scully P.R., Treibel T.A., Fontana M. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol. 2018;71:463–464.
- Castaño A., Narotsky D.L., Hamid N. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879–2887.
- Maurer M.S., Schwartz J.H., Gundapaneni B. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–1016.
- Solomon S.D., Adams D., Kristen A. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: analysis of the APOLLO Study. Circulation. 2019;139:431–443.
- Dasgupta N.R., Benson M. Improved survival of patients with transthyretin amyloid cardiomyopathy with inotersen (TTR specific antisense oligonucleotide) J Am Coll Cardiol. 2019;73:811.
- Gillmore J.D., Maurer M.S., Falk R.H. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–2412.
- Scully P.R., Bastarrika G., Moon J.C., Treibel T.A. Myocardial extracellular volume quantification by cardiovascular magnetic resonance and computed tomography. Curr Cardiol Rep. 2018;20
- Sado D.M., Flett A.S., Banypersad S.M. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart. 2012;98:1436–1441.
- Banypersad S.M., Sado D.M., Flett A.S. Quantification of myocardial extracellular volume fraction in systemic al amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6:34–39.
- Bandula S., White S.K., Flett A.S. Measurement of myocardial extracellular volume fraction by using equilibrium contrast-enhanced CT: validation against histologic findings. Radiology. 2013;269:396–403.
- Treibel T.A., Bandula S., Fontana M. Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. J Cardiovasc Comput Tomogr. 2015;9:585–592.
- Scully P.R., Patel K.P., Treibel T.A. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41:2759–2767.
- Sokolow M., Lyon T.P. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161–186.
- Hancock E.W., Deal B.J., Mirvis D.M., Okin P., Kligfield P., Gettes L.S. AHA/ACCF/HRS Recommendations for the standardization and interpretation of the electrocardiogram: Part V: electrocardiogram changes associated with cardiac chamber hypertrophy: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009;53:992–1002.
- Baumgartner H., Hung J., Bermejo J. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2017;30:372–392.
- Wharton G., Steeds R., Allen J. A minimum dataset for a standard adult transthoracic echocardiogram: a guideline protocol from the British Society of Echocardiography. Echo Res Pract. 2015;2:G9–G24.
- Nagueh S.F., Smiseth O.A., Appleton C.P. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.
- Lang R.M., Badano L.P., Mor-Avi V. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233–271.
- Devereux R.B., Alonso D.R., Lutas E.M. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458.
- Rubin J., Steidley D.E., Carlsson M., Ong M.L., Maurer M.S. Myocardial contraction fraction by M-mode echocardiography is superior to ejection fraction in predicting mortality in transthyretin amyloidosis. J Card Fail. 2018;24:504–511.
- Perugini E., Guidalotti P.L., Salvi F. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076–1084.
- Scully P.R., Morris E., Patel K.P. DPD Quantification in Cardiac Amyloidosis: a Novel Imaging Biomarker. J Am Coll Cardiol Img. 2020;13:1353–1363.
- Nacif M.S., Kawel N., Lee J.J. Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT. Radiology. 2012;264:876–883.
- Nacif M.S., Liu Y., Yao J. 3D left ventricular extracellular volume fraction by low-radiation dose cardiac CT: assessment of interstitial myocardial fibrosis. J Cardiovasc Comput Tomogr. 2013;7:51–57.
- Trattner S., Halliburton S., Thompson C.M. Cardiac-specific conversion factors to estimate radiation effective dose from dose-length product in computed tomography. J Am Coll Cardiol Img. 2018;11:64–74.
- Cavalcante J.L., Rijal S., Abdelkarim I. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson. 2017;19
- Treibel T.A., Fontana M., Gilbertson J.A. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016;9
- González-López E., Gallego-Delgado M., Guzzo-Merello G. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585–2594.
- Damy T., Costes B., Hagège A.A. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37:1826–1834.
- Coles L.S., Young R.D. Supercentenarians and transthyretin amyloidosis: the next frontier of human life extension. Prev Med. 2012;54:S9–S11.
- Auffret V., Webb J.G., Eltchaninoff H. Clinical impact of baseline right bundle branch block in patients undergoing transcatheter aortic valve replacement. J Am Coll Cardiol Intv. 2017;10:1564–1574.
- Watanabe Y., Kozuma K., Hioki H. Pre-existing right bundle branch block increases risk for death after transcatheter aortic valve replacement with a balloon-expandable valve. J Am Coll Cardiol Intv. 2016;9:2210–2216.
- Martinez-Naharro A., Abdel-Gadir A., Treibel T.A. CMR-verified regression of cardiac AL amyloid after chemotherapy. J Am Coll Cardiol Img. 2018;11:152–154.
- Kurita Y., Kitagawa K., Kurobe Y. Estimation of myocardial extracellular volume fraction with cardiac CT in subjects without clinical coronary artery disease: a feasibility study. J Cardiovasc Comput Tomogr. 2016;10:237–241.
- Treibel T.A., López B., González A. Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. Eur Heart J. 2018;39:699–709.
Source: PubMed